IBL HealthCare Limited · PSX:IBLHL
IBL HealthCare — Investor Presentation (November 2026)
15 slides from IBL HealthCare's investor presentation, Nov 2, 2026
Slide 1: Corporate Briefing Session FY2026
IBL HE ALT HCARE LIM ITED Corporate Briefing Session FY2026 November 02, 2026
Slide 2: Agenda: Session outline
AG E N D A Session outline 01 Company overview 02 Financial highlights and strategic refocus 03 Future outlook 04 Question & answers Forward-looking statements: this presentation contains forward-looking statements reflecting management's current views and are not guarantees of future performance. A
Slide 3: Company overview
SECTION 01 Company overview Incorporated as a private limited company in July 1997; listed on the Pakistan Stock Exchange since November 2008. FY2026 AT A GLANCE A subsidiary of The Searle Company Limited, under the ultimate ownership of International Brands (Private) A year of strategic refocus Lim
Slide 4: Purpose and values
SECTION 01 Purpose and values PURPOSE STATEMENT Elevating life by advancing health and well-being for generations to come. Excellence Passion Partnership Integrity Take ownership, deliver A source of energy, Collaborate selflessly and Create transparency; act quality work, strive for entrepreneurial
Slide 5: Financial highlights — 4-year trend
SECTION 02 Financial highlights — 4-year trend FY2023 FY2024 FY2025 FY2026 Net revenue (PKR m) 4,027.9 3,603.4 4,322.5 4,607.1 Gross profit (PKR m) 1,340.4 951.8 1,447.0 1,644.8 Gross margin (%) 33.3 26.4 33.5 35.7 Profit before tax (PKR m) 458.8 28.9 377.1 401.3 Profit after tax (PKR m) 309.0 7.6 2
Slide 6: Financial highlights — FY2026
SECTION 02 Financial highlights — FY2026 Net revenue Gross profit Profit before tax Profit after tax PKR 4.61b PKR 1.64b PKR 401m PKR 220m ▲ 7% ▲ 14% · margin 36% ▲ 6% ▲ 6% · EPS Rs 2.24 FY2026's headline growth is at the Company level absorbs the cost of exiting discontinued portfolios. The next sl
Slide 7: Revenue by business line
SECTION 02 Revenue by business line Major product line (PKR m) FY2025 FY2026 Nutrition 1,655 1,696 Sweetener and Beverages 621 605 Medical and Surgical Disposables 2,046 2,306 Total revenue 4,322 4,607 IBL HealthCare Limited · FY2026 Corporate Briefing Session
Slide 8: Revenue growth, powered by our core business
SECTION 02 Revenue growth, powered by our core business 5,000 PKR millions 597 4,607 4,500 4,322 4,010 4,000 (312) 3,500 3,000 2,500 2,000 1,500 1,000 500 - FY25 Discontinued FY25 excl. Continuing FY26 portfolio discontinued portfolio portfolio Consolidated revenue grew 7% — but that number blends a
Slide 9: Two verticals, sharper focus
SECTION 02 Two verticals, sharper focus Nutrition MSD Global partner brands, alongside our own in-house brands Devices & consumables, plus anesthesia pharmaceuticals Infant Nutrition Blood Banking & Transfusion · Blood bags Mead Johnson · Prep-up Renal Care & Dialysis · Dialyzers Adult Nutrition Vas
Slide 10: Investing in marketing to fuel Nutrition growth
SECTION 02 Investing in marketing to fuel Nutrition growth Total marketing & distribution expense rose 17% to Marketing and Gross profit distribution expenses PKR 1,006m, deliberately ahead of revenue growth, +17% +14% as the Company invested behind brand-building and market development for the Nutr
Slide 11: FY26 tax position: a profitability-driven improvement
SECTION 02 FY26 tax position: a profitability-driven improvement Minimum tax regime (levy) — eliminated by higher profitability One-off prior-year super tax (TY2022) Nil PKR 19.6m Driven by stronger profitability: FY26's margin recovery pushed normal tax liability above the minimum-tax floor, elimin
Slide 12: Focus areas for FY27
SECTION 03 Focus areas for FY27 Deepening the Two Verticals Leveraging Our Partnerships Enhancing Our Talent New launches enhancing local sourcing Our business partners Continued investment in people, building the required skill-sets in focused verticals. Café with people IBL HealthCare Limited · FY
Slide 13: Opportunities and Risks
SECTION 03 Opportunities and Risks Market & Growth Forward-Looking Financial Discipline Governance & Risk Management Outlook Forecasting Resilient demand for Quality & innovation across FX, import cost & Strong governance & Enterprise risk essential health products both verticals geopolitical risks
Slide 14: Questions & Answers
SECTION 04 Questions & Answers
Slide 15: Thank You!
Thank You! IBL HealthCare Limited
IBL HealthCare — Investor Presentation (November 2026) on 6ix